

Correction

# Correction: Mehrling, T.; et al. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. *Antibodies* 2018, 7, 11

Thomas Mehrling <sup>1</sup>, Daniel Soltis <sup>2</sup> and the *Antibodies* Editorial Office <sup>3,\*</sup>

<sup>1</sup> Mundipharma EDO GmbH, Basel CH-4020, Switzerland; thomas.mehrling@edoncology.com

<sup>2</sup> Consultant, Cleveland Heights, OH 441188, USA; dan.soltis@edoncology.com

<sup>3</sup> MDPI, St. Alban-Anlage 66, 4052 Basel, Switzerland

\* Correspondence: antibodies@mdpi.com

Received: 21 August 2018; Accepted: 22 August 2018; Published: 27 August 2018



The Conflict of Interest section of the published paper [1] has been updated as follows:  
“Thomas Mehrling is an employee of Mundipharma EDO, which is currently developing the ADCs EDO-B278 and EDO-B776. Daniel Soltis is a consultant to Mundipharma EDO.”  
The manuscript will be updated and the original will remain online on the article webpage.

## Reference

1. Mehrling, T.; Soltis, D. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. *Antibodies* **2018**, *7*, 11. [[CrossRef](#)]



© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).